Daiichi Sankyo owns the fastest-growing oncology engine in the pharma industry. Within Global Business Development, the Strategic Initiatives team brings a science-forward, capital-informed lens to enterprise decision-making for Daiichi Sankyo’s most senior leadership.

The team’s ADC platform has driven breakout oncology growth, but sustaining that trajectory depends on decisions being made right now. They sought a quantified, peer-grounded analytical foundation to sharpen their strategic planning.

Working with Sleuth, the team built a custom peer database covering 15 peers, 1,550+ assets, and 15 years of deal history. From that one foundation, dozens of analytical cuts traceable to source data and ready for direct use in executive conversations.

The full case study will be coming soon. Follow Sleuth on LinkedIn or X to stay up to date.